XML 22 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events (Details) - Subsequent Event
1 Months Ended 11 Months Ended
Feb. 28, 2020
USD ($)
product_target
$ / shares
Dec. 31, 2020
USD ($)
shares
Subsequent Event [Line Items]    
Agreement restriction, ownership percentage (less than) 5.00%  
Biogen MA Inc | Collaboration and license agreement    
Subsequent Event [Line Items]    
Number of neurological disease gene targets | product_target 12  
Number of product targets selected | product_target 3  
Number of additional neurological disease gene targets | product_target 9  
Target selection period 5 years  
Biogen MA Inc | Collaboration and license agreement | Forecast    
Subsequent Event [Line Items]    
Proceeds from collaborators   $ 125,000,000.0
Biogen MA Inc | Collaboration and license agreement | Pre-approval Milestone    
Subsequent Event [Line Items]    
Maximum milestone payment receivable $ 925,000,000.0  
Biogen MA Inc | Collaboration and license agreement | Sales-based Milestone    
Subsequent Event [Line Items]    
Maximum milestone payment receivable 1,445,000,000.0  
Biogen MA Inc | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones    
Subsequent Event [Line Items]    
Maximum milestone payment receivable $ 2,370,000,000  
Biogen MA Inc | Stock Purchase Agreement    
Subsequent Event [Line Items]    
Agreement restriction expiration period 3 years  
Agreement restriction, percentage of shares held 50.00%  
Agreement provision, expiration period 2 years  
Agreement provision, ownership percentage (less than) 5.00%  
Biogen MA Inc | Stock Purchase Agreement | Forecast    
Subsequent Event [Line Items]    
Sale of stock, number of shares issued in transaction (in shares) | shares   24,420,157
Sale of stock, price per share (in dollars per share) | $ / shares $ 9.2137  
Consideration received from sale of stock   $ 225,000,000.0